Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
Field | Value | Language |
dc.contributor.author | Wheatley, Adam K. | en_AU |
dc.contributor.author | Juno, Jennifer A. | en_AU |
dc.contributor.author | Wang, Jing J. | en_AU |
dc.contributor.author | Selva, Kevin J. | en_AU |
dc.contributor.author | Reynaldi, Arnold | en_AU |
dc.contributor.author | Tan, Hyon-Xhi | en_AU |
dc.contributor.author | Lee, Wen Shi | en_AU |
dc.contributor.author | Wragg, Kathleen M. | en_AU |
dc.contributor.author | Kelly, Hannah G. | en_AU |
dc.contributor.author | Esterbauer, Robyn | en_AU |
dc.contributor.author | Davis, Samantha K. | en_AU |
dc.contributor.author | Kent, Helen E. | en_AU |
dc.contributor.author | Mordant, Francesca L. | en_AU |
dc.contributor.author | Schlub, Timothy E. | en_AU |
dc.contributor.author | Gordon, David L. | en_AU |
dc.contributor.author | Khoury, David S. | en_AU |
dc.contributor.author | Subbarao, Kanta | en_AU |
dc.contributor.author | Cromer, Deborah | en_AU |
dc.contributor.author | Gordon, Tom P. | en_AU |
dc.contributor.author | Chung, Amy W. | en_AU |
dc.contributor.author | Davenport, Miles P. | en_AU |
dc.contributor.author | Kent, Stephen J. | en_AU |
dc.date.accessioned | 2021-06-02T04:55:02Z | |
dc.date.available | 2021-06-02T04:55:02Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | https://hdl.handle.net/2123/25227 | |
dc.description.abstract | The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B cell and T cell dynamics over time in a cohort of patients who have recovered from mild-moderate COVID-19. Binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection. A similar decline in Spike-specific CD4+ and circulating T follicular helper frequencies occurs. By contrast, S-specific IgG+ memory B cells consistently accumulate over time, eventually comprising a substantial fraction of circulating the memory B cell pool. Modelling of the concomitant immune kinetics predicts maintenance of serological neutralising activity above a titre of 1:40 in 50% of convalescent participants to 74 days, although there is probably additive protection from B cell and T cell immunity. This study indicates that SARS-CoV-2 immunity after infection might be transiently protective at a population level. Therefore, SARS-CoV-2 vaccines might require greater immunogenicity and durability than natural infection to drive long-term protection. | en_AU |
dc.language.iso | en | en_AU |
dc.subject | COVID-19 | en_AU |
dc.subject | Coronavirus | en_AU |
dc.title | Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 | en_AU |
dc.type | Article | en_AU |
dc.identifier.doi | 10.1038/s41467-021-21444-5 | |
dc.relation.other | Government of Victoria | en_AU |
dc.relation.other | European Commission | en_AU |
dc.relation.other | Australian Research Council | en_AU |
dc.relation.other | National Health and Medical Research Council | en_AU |
Associated file/s
There are no files associated with this item.
Associated collections